Notice of NIDDK Participation in PAR-20-238, Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
Notice Number:
NOT-DK-21-006

Key Dates

Release Date:

December 2, 2020

Related Announcements

PAR-20-238 - Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will participate, effective immediately, in PAR-20-238, “Intervention Research to Improve Native American Health (R01 Clinical Trial Optional).”

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) supports research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the Institute. Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity and related behaviors (dietary intake and sedentary behavior/physical activity, etc.); nutrition-related disorders and outcomes; hepatitis C; gallbladder disease; H. Pylori infection; kidney diseases; urologic diseases; hematologic diseases; and metabolic, gastrointestinal, hepatic, and renal complications from infection with HIV. Many of these disease and conditions impose disproportionate burden on the Native American population.

NIDDK is particularly interested in community-engaged approaches where investigators partner with community members and key stakeholders in identifying study priorities, activities, and/or outcomes to promote equity and ensure successful strategies have optimal potential for sustainability. Appropriate topics for investigation would include but are not limited to:

  • Better understanding of screening, diagnosis, incidence, and prevalence of NIDDK diseases in Native populations with an emphasis on identifying factors that help inform treatment development, practices, or policies designed to reduce or eliminate disparities;
  • Testing approaches that influence healthcare delivery in Native American populations to reduce disparities in prevention and treatment of NIDDK diseases or conditions;
  • Studies of effects of medications or other therapies for prevention or treatment of NIDDK diseases or conditions in Native American populations;
  • Studies of or interventions targeting social, environmental or behavioral determinants of health that may contribute to risk for development and progression of NIDDK diseases and related complications in Native American populations; and
  • Evaluation of natural experiments, including the influence of new policies or programs implemented in Native communities, within healthcare organizations, or other entities that are likely to influence risk for the development and progression of NIDDK diseases and related complications.


The following sections of PAR-20-238 have been modified (shown in italics) to reflect the NIDDK’s participation in this FOA:
 

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Library of Medicine (NLM)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)


Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.279, 93.399, 93.273, 93.855, 93.846, 93.286, 93.121, 93.113, 93.242, 93.307, 93.361, 93.879, 93.847

Section VII. Agency Contacts

Scientific/Research Contact(s)
Mary Evans, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-0598
Email: evansmary@niddk.nih.gov

Financial/Grants Management Contact(s)
Elizabeth Gutierrez
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8844

Email: Gutierrezel@niddk.nih.gov


All other aspects of PAR-20-238 remain unchanged.

Inquiries

Please direct all inquiries to:

Mary Evans, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-0598
Email: evansmary@niddk.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices